论文部分内容阅读
目的:研究益精稳压方对自发性高血压大鼠(SHR)不同阶段血压及内皮损伤标志物水平的影响。探讨益精稳压方早期干预高血压的作用机制。方法:采用自发性高血压大鼠(SHR),分为模型组、中药干预低剂量组、中剂量组、高剂量组,并设WKY大鼠空白对照组,共5组。观察各组治疗前、治疗中、治疗后血压、ET-1及TM含量,免疫组织化学研究益精稳压方对自发性高血压大鼠对CD62P表达及vWF水平的影响。结果:与空白组相比,模型组以及中药干预组血压、ET-1及TM水平明显上升,差异具显著统计学意义(P<0.01),与模型组相比,低剂量组与模型组差异不明显,中剂量组、高剂量组血压、ET-1及TM水平下降,具统计学意义(P<0.05),同组大鼠前后比较,中剂量组、高剂量组大鼠血压升高进展延缓,ET-1及TM水平升高幅度下降;免疫组化证明:与模型组相比较,益精稳压方各给药组vWF、CD62P的表达受到不同程度的抑制,中药高剂量组和中剂量组统计学上有显著性差异(P<0.05或P<0.01)。结论:益精稳压方早期干预自发性高血压大鼠高血压发病早期,可延缓高血压的发生、发展,降低自发性高血压大鼠ET-1及TM含量,而且能抑制SHR大鼠vWF、CD62P的表达,保护血管内皮细胞,减少血小板的活化。
Objective: To study the effect of Yijing regulator on the levels of blood pressure and endothelial damage markers in different stages of spontaneously hypertensive rats (SHR). To investigate the mechanism of early intervention of hypertension by Yijing regulator. METHODS: Spontaneously hypertensive rats (SHR) were divided into model group, Chinese medicine intervention low-dose group, middle-dose group and high-dose group, and WKY rat blank control group. There were 5 groups. The blood pressure, ET-1, and TM contents before, during, and after treatment in each group were observed. The effect of Yijing regulator on the expression of CD62P and vWF levels in spontaneously hypertensive rats was examined by immunohistochemistry. Results: Compared with the blank group, the blood pressure, ET-1 and TM levels in the model group and the TCM intervention group increased significantly (P<0.01). Compared with the model group, the difference between the low-dose group and the model group was significant. Insignificantly, the blood pressure, ET-1 and TM levels in the middle-dose group and the high-dose group decreased, with statistical significance (P<0.05). Compared with the rats in the same group before and after, the blood pressure increased in the middle-dose group and the high-dose group. Delayed, the increase of ET-1 and TM levels decreased; immunohistochemistry proved that compared with the model group, the expression of vWF and CD62P was inhibited to varying degrees in each group of Yijing Regulator. There was a statistically significant difference between the dose groups (P<0.05 or P<0.01). CONCLUSION: Early intervention of Yijing Regulator in the early stage of hypertension in spontaneously hypertensive rats can delay the occurrence and development of hypertension, decrease the content of ET-1 and TM in spontaneously hypertensive rats, and inhibit the vWF in SHR rats. The expression of CD62P protects vascular endothelial cells and reduces platelet activation.